Bronchodilator effects of prostacyclin (PGI2) in dogs and guinea pigs.
prostacyclin (PGI2), a recently discovered unstable product in the biosynthetic conversion of prostaglandin endoperoxides, was examined for bronchopulmonary actions. in anesthetized dogs, PGI2 given i.v. (0.3-30.0 microgram/kg) and by aerosol (0.002-0.2%) inhibited significantly PGF2 alpha-induced increases in pulmonary resistance and decreases in dynamic lung compliance in a dose-related fashion. Intrinsically, PGI2 affected resting bronchopulmonary and cardiac functions minimally, but decreased peripheral and pulmonary vascular pressures. PGI2 (0.1-10 mg/kg, i.p.) afforded protection against histamine-induced asphyxial collapse in normal guinea pigs and ovalbumin-induced anaphylaxis in sensitized animals. Cumulative concentrations of PGI2 (1.0 x 10(-9)--3.0 x 10(-4) M) relaxed contractions of the isolated guine pig trachea produced by carbachol. These bronchodilator and hemodynamic effects could not be ascribed to the stable metabolic product of PGI2, because 6-keto-PGF1 alpha was inactive or markedly less active than PGI2 in these test systems. The results of this investigation suggest that PGI2 possesses considerable bronchodilator and vasodilator activity in experimental animal systems.
D015121:6-Ketoprostaglandin F1 alpha; D000758:Anesthesia; D000818:Animals; D001993:Bronchodilator Agents; D002217:Carbachol / Q000494:pharmacology; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006168:Guinea Pigs; D006439:Hemodynamics; D008168:Lung / Q000187:drug effects; D008297:Male; D011453:Prostaglandins / Q000494:pharmacology*; D011460:Prostaglandins F / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects
D001993:Bronchodilator Agents; D011453:Prostaglandins; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D015121:6-Ketoprostaglandin F1 alpha; D002217:Carbachol; D011464:Epoprostenol